H

ello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that familiar routine of meetings, deadlines, and the like has returned. You knew this would happen, though, yes? What else can one do but cope by firing up the coffee kettle for a few cups of stimulation. Our choice today is old-fashioned cinnamon latte in the event you are looking for ideas. Meanwhile, here are a few items of interest to help you along. Hope your journey is rewarding and, as always, do keep in touch …

GlaxoSmithKline (GSK) is facing “unprecedented” demand for its new shingles vaccine Shingrix, suggesting the product could be a bigger money-spinner than the company and analysts initially thought, Reuters informs us. More than 1.5 million Americans have received Shingrix since the end of last year, but U.S. health officials have warned of shortages. Meanwhile, analysts currently forecast peak annual sales of around $2 billion but this could be doubled, according to Exane BNP if Shingrix can achieve market penetration rates of around 60 percent.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy